TY -的T1 -利妥昔单抗治疗多发性硬化和女性在怀孕前视neuromyelitis:案例系列和系统综述。乔(P4.359) JF -首页神经-神经学六世- 90 - 15补充SP - P4.359 AU -莱利波维盟Gitanjali Das AU -文森特Damotte AU -杰弗里·盖尔芬德盟-卡洛琳贝文AU -布鲁斯克里族盟林恩做非盟- Ari绿盟斯蒂芬·豪泽Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/P4.359.abstract N2 -目的:评估安全的利妥昔单抗治疗女性在怀孕前和多发性硬化症(MS) neuromyelitis视(动)报告一个单中心案例系列,医学文献的系统回顾。背景:女性被女士与动不成比例的影响。管理疾病修饰治疗(儿童)在怀孕前是一个持续的挑战神经学家,尤其是具有高复发风险的妇女的情况,和严重的“反弹”女士疾病活动后停止某些儿童发展。中心案例系列:加州大学旧金山分校多发性硬化和神经炎症患者病历进行识别与动接触利妥昔单抗在怀孕前女士。系统回顾:提供一个科学的框架,这些观察,已发表的研究(任何孕产妇指示)使用关键词“怀孕”和“美罗华”在Pubmed系统地识别,谷歌学术搜索和EMBASE;22包括审查。案例系列:十二个怀孕正在进行(3)被确定在11个女性(8女士,3动)6个月内接受利妥昔单抗的观念。所有9完成怀孕导致活产,健康的新生儿(1输给了跟进)。一个产妇产后观察复发(动)。系统回顾:102年怀孕与利妥昔单抗在6个月内使用概念(任何孕产妇指示),导致78人口出生数量的,12报道自然流产。54个活产的孕龄报道,31日在术语(37周+)和2 32周之前发生。 When checked, B-cell counts were low in 39% of newborns, and normalized within 6 months.Conclusions: No major safety signal was observed with rituximab use within 6 months of conception. Beyond the need for monitoring neonatal B cells, these observations support prospectively monitoring a larger cohort of women to determine whether rituximab may safely protect against relapses in women with MS and NMO who are planning a pregnancy.Disclosure: Dr Bove has nothing to disclose. Dr. has nothing to disclose. Dr. Damotte has nothing to disclose. Dr. Gelfand has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with . Dr. Bevan has nothing to disclose. Dr. Cree has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Biogen, EMD Serono, GeNEuro, Novartis, Sanofi Genzyme. Dr. Cree has received research support from Acorda, Hoffman La Roche, MedImmune, Novartis, Receptos and Teva. Dr. Do has nothing to disclose. Dr. Green has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Green has received personal compensation for activities with Inception Sciences, Mylan Pharma, Medimmune, and Bionure. Dr. Green has received personal compensation in an editorial capacity for Dr. Green has received personal compensation for serving on the board of Inception Sciences. Dr. Green has received research support from Dr. Green has received research support from Inception Sciences, Biogen, and Novartis. Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Symbiotix, Annexon, Bionure, Molecular Stethoscope. Dr. Hauser has received compensation for serving on the Board of Directors of Neurona. ER -